<DOC>
	<DOCNO>NCT02786290</DOCNO>
	<brief_summary>This First Human study ass feasibility , safety effectiveness Zenflow Spring System relieve symptom obstructive Benign Prostatic Hyperplasia ( BPH ) .</brief_summary>
	<brief_title>The Zenflow Spring System Feasibility Safety Study</brief_title>
	<detailed_description>The purpose Zenflow Study evaluate feasibility safety novel prostatic urethral implant treatment Lower Urinary Tract Symptoms ( LUTS ) arise due bladder outlet obstruction ( BOO ) , secondary presence Benign Prostatic Hypertrophy ( BPH ) . Effectiveness also measure . It intend feature Zenflow Spring provide effective office-based treatment management therapy BPH little side effect .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<criteria>1 . 50 80 year age 2 . Baseline IPSS score &gt; 13 , baseline Quality Life ( Qol ) question score &gt; 3 3 . Prostate volume 25 80 cc Trans Rectal Ultrasound ( TRUS ) , measure within past 90 day 4 . Anterior prostatic urethral length 2.5 4.0 cm cystoscopy , measure bladder neck verumontanum . TRUS accept primary screening measure . 5 . Failed intolerant medication regimen treatment LUTS . New Zealand : A maximum 5 participant acute chronic urinary retention may include study provide meet entry criterion . Exclusion exemptions patient describe 4a , 5a exempt # 6 . Participants exclude participate trial meet follow criterion : 1 . Obstructive median prostatic lobe high bladder neck 2 . Urethral stricture , meatal stenosis , bladder neck obstruction either current , recurrent require 2 dilatation 3 . Elevated Prostate Specific Antigen ( PSA ) ( age 5070 PSA ≥4 ; age 70+ PSA ≥6.5 ) unless negative biopsy within last 3 month , positive biopsy 4 . Postvoid residual volume ( PVR ) &gt; 250 ml , acute retention 4a . No maximum post void residual volume require patient acute chronic urinary retention . ( New Zealand Only , 5 patient ) 5 . Peak urinary flow rate &gt; 12 ml/second , ≥ 125 ml void volume baseline . 5a . No maximum urinary flow minimum voided volume require participant acute chronic urinary retention . ( New Zealand Only , 5 patient ) 6 . History chronic urinary retention . ( New Zealand Only , 5 patient ) 7 . History neurogenic bladder 8 . Compromised renal function ( e.g. , serum creatinine &gt; 1.8 mg/dl ) 9 . Concomitant Urinary Tract Infection ( UTI ) 10 . Concomitant bladder stone 11 . Confirmed suspected prostate/bladder cancer 12 . Previous pelvic irradiation radical pelvic surgery 13 . Previous prostate surgery , stent implantation , laser prostatectomy , hyperthermia another invasive treatment prostate 14 . Chronic prostatitis , recur prostatitis within past 12 month 15 . Serious concurrent medical condition uncontrolled diabetes 16 . Known allergy nickel 17 . Life expectancy le 12 month 18 . Use concomitant medication ( e.g. , anticholinergic , antispasmodic antidepressant ) affect bladder function 19 . Anticoagulant , antiplatelet , thrombolytic medication Acetylsalicylic Acid ( ASA ) Clopidogrel . ASA Clopidogrel must cease 7 day prior procedure . 20 . 5reductase inhibitor within 6 month pretreatment evaluation unless evidence drug dose least 6 month stable void pattern ( drug dose alter discontinue entrance throughout study ) . 21. blocker within 2 week pretreatment evaluation unless evidence drug dose least 6 month stable void pattern ( drug dose alter discontinue entrance throughout study ) . 22 . Future fertility concern 23 . Any severe illness might prevent study completion would confound study result</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>